Pralatrexate
Top View
- Clinically Relevant Concentrations of Anticancer Drugs: a Guide for Nonclinical Studies Dane R
- Threshold of Toxicological Concern (TTC) for Anticancer Compounds
- Single Agent and Combination Studies of Pralatrexate and Molecular Correlates of Sensitivity
- Cross Discipline Team Leader Review
- Treatment and Clinical Trials for PTCL
- EMA/PDCO Summary Report on the Review of the List of Granted Class Waivers
- Emetogenic Potential of Antineoplastic Agents
- Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration
- Hazardous Chemical Agents (Anti-Neoplastic, Carcinogens, Reproductive Hazards, Neurotoxic)
- Peripheral T-Cell Lymphoma
- Extract from the Clinical Evaluation Report for Pralatrexate
- Pralatrexate Monograph
- Pralatrexate Injection), for Intravenous Use Hepatic Toxicity: Monitor for Toxicity
- Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval
- June 30, 2021 Total Approvals 269 This Report Will Be Updated January and July of Every Year
- Cancer Drug Costs for a Month of Treatment at Initial Food and Drug
- [2016]. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016
- FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option